Revisiting ANCA-associated vasculitis in systemic sclerosis: Clinical, serological and immunogenetic factors

Rheumatology (United Kingdom)

Volumn 52, Issue 10, 2013, Pages 1824-1831

  Derrett Smith, Emma C ^a   Nihtyanova, Svetlana I ^a   Harvey, Jennifer ^b   Salama, Alan D ^a   Denton, Christopher P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Anti neutrophil cytoplasmic antibodies; Genetics; Scleroderma; Vasculitis

Indexed keywords

ENZYME ANTIBODY; FIBRILLARIN ANTIBODY; MYELOPEROXIDASE ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY; HLA D ANTIGEN; MYELOBLASTIN; PEROXIDASE; RIBONUCLEOPROTEIN, U3 SMALL NUCLEOLAR; SMALL NUCLEOLAR RIBONUCLEOPROTEIN;

ADULT; ANCA ASSOCIATED VASCULITIS; ARTICLE; CLINICAL FEATURE; FEMALE; GLOMERULONEPHRITIS; GRANULOMATOSIS; HAPLOTYPE; HISTOPATHOLOGY; HLA SYSTEM; HUMAN; IMMUNOFLUORESCENCE; IMMUNOGENETICS; LOW DRUG DOSE; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RENOVASCULAR DISEASE; SEROLOGY; SKIN BIOPSY; SYSTEMIC SCLEROSIS; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODIES; BIOPSY; BLOOD; CASE REPORT; GENETIC PREDISPOSITION; GENETICS; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; KIDNEY; METHODOLOGY; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SCLERODERMA; SKIN; VASCULITIS;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODIES; GENETICS; SCLERODERMA; VASCULITIS;

ADULT; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; AUTOANTIBODIES; BIOPSY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HISTOCOMPATIBILITY TESTING; HLA-D ANTIGENS; HUMANS; KIDNEY; MALE; MIDDLE AGED; MYELOBLASTIN; PEROXIDASE; RETROSPECTIVE STUDIES; RIBONUCLEOPROTEINS, SMALL NUCLEOLAR; SCLERODERMA, SYSTEMIC; SKIN;

EID: 84888773951     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket213     Document Type: Article

References (31)

1. Steen VD. Scleroderma renal crisis. Rheum Dis Clin North Am 2003;29:315-33.
2. Penn H, Howie AJ, Kingdon EJ et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 2007;100:485-94.
3. Endo H, Hosono T, Kondo H. Antineutrophil cytoplasmic autoantibodies in 6 patients with renal failure and systemic sclerosis. J Rheumatol 1994;21:864-70.
4. Arad U, Balbir-Gurman A, Doenyas-Barak K et al. Anti-neutrophil antibody associated vasculitis in systemic sclerosis. Semin Arthritis Rheum2011;41:223-9.
5. Shanmugam VK, Steen VD. Renal manifestations in scleroderma: evidence subclinical renal disease as a marker of vasculopathy. Int J Rheumatol 2010. Advance Access published 17 August 2010, doi:10.1155/2010/538589.
6. Falk RJ, Gross WL, Guillevin L et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Ann Rheum Dis 2011;70:704.
7. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92.
8. Grypiotis P, Cozzi F, Ruffatti A. Autoantibodies to bactericidal/permeability-increasing protein and cathepsin G in systemic sclerosis. J Rheumatol 2004;31:1468-9.
9. Khanna D, Aggarwal A, Bhakuni DS et al. Bactericidal/permeability-increasing protein and cathepsin G are the major antigenic targets of antineutrophil cytoplasmic autoantibodies in systemic sclerosis. J Rheumatol 2003;30:1248-52.
10. Caramaschi P, Biasi D, Tonolli E et al. Antineutrophil cytoplasmic antibodies in scleroderma patients: first report of a case with anti-proteinase 3 antibodies and review of the literature. Joint Bone Spine 2002;69:177-80.
11. Liang KP, Michet CJ. ANCA-associated vasculitis in scleroderma: a case series of fourteen patients. Rheumatol Rep 2011;3(1).
12. Akkara Veetil BM, Schimmer BM. A case of limited systemic sclerosis with p-ANCA, complicated by multiple cerebral hemorrhages. Rheumatol Int 2009;29:325-9.
13. Silman A, Jannini S, Symmons D et al. An epidemiological study of scleroderma in the West Midlands. Br J Rheumatol 1988;27:286-90.
14. Scott DGI, Watts RA. Systemic vasculitis: epidemiology, classification and environmental factors. Ann Rheum Dis 2000;59:161-3.
15. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
16. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975;292:344-7.
17. Lyons PA, Rayner TF, Trivedi S et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012;367:214-23.
18. Arulkumaran N, Periselneris N, Gaskin G et al. Interstitial lung disease and ANCA-associated vasculitis: a retrospective observational cohort study. Rheumatology 2011;50:2035-43.
19. Zhou X, Lee JE, Arnett FC et al. HLA DPB1 and HLA-DPB2 are genetic loci for systemic sclerosis: a genome-wide association study in Koreans with replication in North Americans. Arthritis Rheum 2009;60:3807-14.
20. Arnett FC, Gourh P, Shete S et al. Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. Ann Rheum Dis 2010;69:822-7.
21. Radstake TR, Gorlova O, Rueda B et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet 2010;42:426-9.
22. Merkel PA, Polisson RP, Chang Y et al. Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. Ann Intern Med 1997;126:866-73.
23. Quéméneur T, Mouthon L, Cacoub P et al. Systemic vasculitis during the course of systemic sclerosis: report of 12 cases and review of the literature. Medicine 2013;92:1-9.
24. Hillis GS, Khan IH, Simpson JG et al. Scleroderma, Dpenicillamine treatment, and progressive renal failure associated with positive antimyeloperoxidase antineutrophil cytoplasmic antibodies. Am J Kidney Dis 1997;30:279-81.
25. Karpinski J, Jothy S, Radoux V et al. D-penicillamineinduced crescentic glomerulonephritis and antimyeloperoxidase antibodies in a patient with scleroderma. Case report and review of the literature. Am J Nephrol 1997;17:528-32.
26. Bhanji A, Karim M. Pulmonary fibrosis-an uncommon manifestation of anti-myeloperoxidase-positive systemic vasculitis? NDT Plus 2010;3:351-3.
27. Eschun GM, Mink SN, Sharma S. Pulmonary interstitial fibrosis as a presenting manifestation in perinuclear antineutrophilic cytoplasmic antibody microscopic polyangiitis. Chest 2003;123:297-301.
28. Bunn CC, Denton CP, Shi-Wen X et al. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol 1998;37:15-20.
29. Tormey VJ, Bunn CC, Denton CP et al. Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology 2001;40:1157-62.
30. Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998;41:1613-9.
31. Kamen DL, Wigley FM, Brown AN. Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis in scleroderma-a different kind of renal crisis. J Rheumatol 2006;33:1886-8.